Continuous Dopaminergic Stimulation in Parkinson’s Disease

Proceedings of the Workshop in Alicante, Spain, September 22–24, 1986

  • J. A. Obeso
  • R. Horowski
  • C. D. Marsden
Conference proceedings

Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Continuous dopaminergic stimulation in Parkinson’s disease

    1. Front Matter
      Pages 1-1
    2. T. N. Chase, M. M. Mouradian, G. Fabbrini, J. L. Juncos
      Pages 3-10
    3. J. A. Obeso, M. R. Luquin, J. Vaamonde, J. M. Martînez Lage
      Pages 17-25
    4. F. Stocchi, S. Ruggieri, A. Antonini, F. Baronti, G. Brughitta, P. Bellantuono et al.
      Pages 27-33
    5. P. H. S. Critchley, F. Grandas Perez, N. P. Quinn, J. D. Parkes, C. D. Marsden
      Pages 55-60
    6. C. Chouza, J. L. Caamaño, Ofrenda de Medina, Ruth Aljanati, A. Scaramelli, Susana Romero
      Pages 61-70
    7. W. Krause, B. Nieuweboer, St. Ruggieri, F. Stocchi, I. Suchy
      Pages 71-74
    8. M. Fernandez Pardal, Federico Micheli, Mabel Gatto, Natividad Perez y Gonzalez
      Pages 75-84
    9. O. S. Gershanik, O. Scipioni, Silvia García
      Pages 85-90
  3. Complications in treatment

  4. Continuous dopaminergic stimulation experimental studies

    1. Front Matter
      Pages 139-139
    2. P. Jenner, S. Boyce, C. D. Marsden
      Pages 161-175
  5. Biochemical basis of diagnostic and therapeutic problems

  6. Present state and future developments

    1. Front Matter
      Pages 241-247
    2. R. Horowski, C. D. Marsden, J. A. Obeso
      Pages 249-252
  7. Back Matter
    Pages 253-255

About these proceedings


At this meeting, a number of critical groups confirmed and extended the original findings by J.A. Obeso and his colleagues. These authors found that continuous s.c. infusion of lisuride, a watersoluble dopaminergic 8- -aminoergoline with dopaminergic properties which can be injected or infused, can improve - sometimes quite considerably - motor function in severely disabled fluctuating Parkinsonian patients. The concurrent use of the peripheral dopamine antagonist domperidone attenuates or prevents side effects related to the stimulation of "peripheral" dopamine receptors, including the chemoreceptor trigger zone and some areas of the hypothalamus outside the blood-brain barrier. The clinical results discussed in this volume may not only be a basis for further improvements in our knowledge and therapeutic strategies in Parkinsonism, they point to the so far neglected importance of different ways of stimulating neurological or other systems, e.g. discontinous, oscillatory effects caused by frequent oral application vs. continuous stimulation as described here with the lisuride s.c. infusion. Similar concepts have to be discussed and investigated in neurological disorders. In this respect, this multidisciplinary meeting and its publication may offer new ideas and concepts for therapy in general, in addition to its potential application in the treatment of the complications of Parkinson's disease.


PET Parkinson brain dopamine drug drug delivery kinetics pharmacokinetics positron emission tomography (PET) research therapy

Editors and affiliations

  • J. A. Obeso
    • 1
  • R. Horowski
    • 2
  • C. D. Marsden
    • 3
  1. 1.Clinica UniversitariaPamplonaSpain
  2. 2.HA Klinische Forschung IISchering AGBerlinGermany
  3. 3.University Department of Clinical NeurologyThe National Hospital for Nervous DiseasesLondonUK

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag/Wien 1988
  • Publisher Name Springer, Vienna
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-211-82034-6
  • Online ISBN 978-3-7091-8954-2
  • Series Print ISSN 0303-6995
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Consumer Packaged Goods